High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

AbstractFifteen patients with myelodysplastic/myeloproliferative disorders were treated with high‐dose cytosine arabinoside therapy. While severe toxicity was produced in every patient, only two of the 15 patients entered complete remission and two achieved partial remission status. The therapeutic responses were confined to patients who had severe myelofibrosis of apparently recent onset.

authors

Preisler, HD
Raza, A
Barcos, M
Azarnia, N
Larson, R
Browman, G
Walker, Irwin Ronald
Grunwald, H
D'Arrigo, P
Stein, A
Bloom, M
Goldberg, J
Gottlieb, A
Bennett, J
Kirshner, J
Priore, R

status

published

publication date

October 1986

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
Adult (MeSH)
Aged (MeSH)
Clinical Trials as Topic (MeSH)
Cytarabine (MeSH)
Drug Administration Schedule (MeSH)
Humans (MeSH)
Immunology (Science Metrix)
Middle Aged (MeSH)
Myelodysplastic Syndromes (MeSH)
Myeloproliferative Disorders (MeSH)
Platelet Count (MeSH)
Preleukemia (MeSH)
Thrombocytopenia (MeSH)

published in

American Journal of Hematology Journal